Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
Year: 2008
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, The University of Texas at San Antonio Health Science Center, Medizinische Fakultät Mannheim, Hammersmith Hospital, Amsterdam UMC Location Vrije Universiteit Amsterdam, Novartis (United States), Novartis (Switzerland), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2559459637